5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1. 2014

Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Biomedical Sciences, Tokyo Denki University, Saitama, Japan.

5-Aminolevulinic acid (5-ALA) is the naturally occurring metabolic precursor of heme. Heme negatively regulates the Maf recognition element (MARE) binding- and repressing-activity of the Bach1 transcription factor through its direct binding to Bach1. Heme oxygenase (HO)-1 is an inducible enzyme that catalyzes the rate-limiting step in the oxidative degradation of heme to free iron, biliverdin and carbon monoxide. These metabolites of heme protect against apoptosis, inflammation and oxidative stress. Monocytes and macrophages play a critical role in the initiation, maintenance and resolution of inflammation. Therefore, the regulation of inflammation in macrophages is an important target under various pathophysiological conditions. In order to address the question of what is responsible for the anti-inflammatory effects of 5-ALA, the induction of HO-1 expression by 5-ALA and sodium ferrous citrate (SFC) was examined in macrophage cell line (RAW264 cells). HO-1 expression induced by 5-ALA combined with SFC (5-ALA/SFC) was partially inhibited by MEK/ERK and p38 MAPK inhibitor. The NF-E2-related factor 2 (Nrf2) was activated and translocated from the cytosol to the nucleus in response to 5-ALA/SFC. Nrf2-specific siRNA reduced the HO-1 expression. In addition, 5-ALA/SFC increased the intracellular levels of heme in cells. The increased heme indicated that the inactivation of Bach1 by heme supports the upregulation of HO-1 expression. Taken together, our data suggest that the exposure of 5-ALA/SFC to RAW264 cells enhances the HO-1 expression via MAPK activation along with the negative regulation of Bach1.

UI MeSH Term Description Entries
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004790 Enzyme Induction An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis. Induction, Enzyme
D005296 Ferrous Compounds Inorganic or organic compounds that contain divalent iron. Compounds, Ferrous
D000622 Aminolevulinic Acid A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS. 5-Amino Levulinic Acid,5-Aminolaevulinate,5-Aminolevulinate,Aminolevulinic Acid Hydrochloride,Delta-Aminolevulinic Acid,Levulan,5 Amino Levulinic Acid,5 Aminolaevulinate,5 Aminolevulinate,Acid Hydrochloride, Aminolevulinic,Acid, 5-Amino Levulinic,Acid, Aminolevulinic,Acid, Delta-Aminolevulinic,Delta Aminolevulinic Acid,Hydrochloride, Aminolevulinic Acid,Levulinic Acid, 5-Amino
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D048049 Extracellular Signal-Regulated MAP Kinases A mitogen-activated protein kinase subfamily that is widely expressed and plays a role in regulation of MEIOSIS; MITOSIS; and post mitotic functions in differentiated cells. The extracellular signal regulated MAP kinases are regulated by a broad variety of CELL SURFACE RECEPTORS and can be activated by certain CARCINOGENS. ERK MAP Kinase,ERK MAP Kinases,Extracellular Signal-Regulated Kinase,Extracellular Signal-Regulated Kinases,Extracellular Signal-Regulated MAP Kinase,MAP Kinases, Extracellular Signal-Regulated,Extracellular Signal Regulated Kinase,Extracellular Signal Regulated Kinases,Extracellular Signal Regulated MAP Kinase,Extracellular Signal Regulated MAP Kinases,Kinase, ERK MAP,Kinase, Extracellular Signal-Regulated,Kinases, Extracellular Signal-Regulated,MAP Kinase, ERK,MAP Kinases, Extracellular Signal Regulated,Signal-Regulated Kinase, Extracellular
D048051 p38 Mitogen-Activated Protein Kinases A mitogen-activated protein kinase subfamily that regulates a variety of cellular processes including CELL GROWTH PROCESSES; CELL DIFFERENTIATION; APOPTOSIS; and cellular responses to INFLAMMATION. The P38 MAP kinases are regulated by CYTOKINE RECEPTORS and can be activated in response to bacterial pathogens. Mitogen-Activated Protein Kinase p38,p38 Mitogen-Activated Protein Kinase,p38 MAP Kinase,p38 MAPK,p38 Protein Kinase,p38 SAPK,MAP Kinase, p38,MAPK, p38,Mitogen Activated Protein Kinase p38,Protein Kinase, p38,p38 Mitogen Activated Protein Kinase,p38 Mitogen Activated Protein Kinases
D050976 Basic-Leucine Zipper Transcription Factors A large superfamily of transcription factors that contain a region rich in BASIC AMINO ACID residues followed by a LEUCINE ZIPPER domain. Basic-Leucine Zipper Transcription Factor,GBF bZIP Transcription Factor,bZIP G-Box Binding Factor,bZIP G-Box Binding Factors,bZIP Protein,bZIP Transcription Factor,GBF bZIP Transcription Factors,bZIP Proteins,bZIP Transcription Factors,Basic Leucine Zipper Transcription Factor,Basic Leucine Zipper Transcription Factors,Factor, bZIP Transcription,Protein, bZIP,Transcription Factor, bZIP,Transcription Factors, bZIP,bZIP G Box Binding Factor,bZIP G Box Binding Factors

Related Publications

Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
August 2018, European journal of pharmacology,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
June 2023, Molecular biology reports,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
October 2021, International journal of molecular sciences,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
February 2016, Biochemical and biophysical research communications,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
March 2021, Diabetes,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
December 2021, Experimental and therapeutic medicine,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
September 1985, Experimental hematology,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
June 2023, International journal of molecular sciences,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
October 2007, Journal of inorganic biochemistry,
Yoshiaki Nishio, and Masayuki Fujino, and Mingyi Zhao, and Takuya Ishii, and Masahiro Ishizuka, and Hidenori Ito, and Kiwamu Takahashi, and Fuminori Abe, and Motowo Nakajima, and Tohru Tanaka, and Shigeru Taketani, and Yukitoshi Nagahara, and Xiao-Kang Li
October 2013, American journal of physiology. Renal physiology,
Copied contents to your clipboard!